-
公开(公告)号:US20240043393A1
公开(公告)日:2024-02-08
申请号:US18158046
申请日:2023-01-23
发明人: Boyu ZHONG , Lijun SUN , Heping SHI , Jing LI , Chuo CHEN , Zhijian CHEN
IPC分类号: C07D277/34 , C07D417/14 , A61K31/429 , A61K31/4365 , A61K31/4439 , A61K31/506 , A61K31/519 , A61K31/427 , C07D277/40 , A61K31/437 , A61K31/426 , A61K31/381 , A61K31/433 , A61K31/4709 , A61K39/39 , A61K45/06 , A61K31/454 , A61K31/4725 , A61K31/497 , A61K31/4985 , A61K31/501 , C07D277/36 , C07D403/06 , C07D417/04 , C07D417/06 , C07D417/10 , C07D417/12 , C07D471/04 , C07D495/04 , C07D513/04
CPC分类号: C07D277/34 , C07D513/04 , A61K31/429 , A61K31/4365 , A61K31/4439 , A61K31/506 , A61K31/519 , A61K31/427 , C07D277/40 , A61K31/437 , A61K31/426 , A61K31/381 , A61K31/433 , A61K31/4709 , A61K39/39 , A61K45/06 , A61K31/454 , A61K31/4725 , A61K31/497 , A61K31/4985 , A61K31/501 , C07D277/36 , C07D403/06 , C07D417/04 , C07D417/06 , C07D417/10 , C07D417/12 , C07D471/04 , C07D495/04 , C07D417/14
摘要: Disclosed are novel compounds of Formula I that are cGAS antagonists, methods of preparation of the compounds, pharmaceutical compositions comprising the compounds, and their use in medical therapy.
-
公开(公告)号:US20190210971A1
公开(公告)日:2019-07-11
申请号:US16241851
申请日:2019-01-07
IPC分类号: C07D215/38 , A61K31/47 , C07D277/56 , C07D277/40 , C07C229/60 , C07C229/56 , C07C215/68 , A61K31/44 , A61K31/435 , A61K31/426 , A61K31/423 , A61K31/41 , A61K31/4418 , A61K31/4706
CPC分类号: C07D215/38 , A61K31/41 , A61K31/423 , A61K31/426 , A61K31/435 , A61K31/44 , A61K31/4418 , A61K31/47 , A61K31/4706 , C07C215/68 , C07C229/56 , C07C229/60 , C07D277/40 , C07D277/56
摘要: Compositions and methods for treating macular degeneration and other forms of retinal disease whose etiology involves the accumulation of A2E and/or lipofuscin, and, more specifically, for preventing the formation and/or accumulation of A2E are disclosed
-
公开(公告)号:US20180230115A1
公开(公告)日:2018-08-16
申请号:US15953494
申请日:2018-04-15
发明人: Boyu ZHONG , Lijun SUN , Heping SHI , Jing Li , Chuo CHEN , Zhijian CHEN
IPC分类号: C07D277/34 , C07D417/06 , A61K31/4439 , C07D417/04 , A61K31/4725 , A61K31/497 , A61K31/506 , C07D403/06 , A61K31/501 , C07D513/04 , A61K31/429 , C07D277/36 , C07D417/12 , C07D495/04 , A61K31/4365 , C07D417/10 , A61K31/4985 , A61K31/519 , C07D417/14 , C07D471/04 , A61K31/454
CPC分类号: C07D277/34 , A61K31/381 , A61K31/426 , A61K31/427 , A61K31/429 , A61K31/433 , A61K31/4365 , A61K31/437 , A61K31/4439 , A61K31/454 , A61K31/4709 , A61K31/4725 , A61K31/497 , A61K31/4985 , A61K31/501 , A61K31/506 , A61K31/519 , A61K39/39 , A61K45/06 , C07D277/36 , C07D277/40 , C07D403/06 , C07D417/04 , C07D417/06 , C07D417/10 , C07D417/12 , C07D417/14 , C07D471/04 , C07D495/04 , C07D513/04 , A61K2300/00
摘要: Disclosed are novel compounds of Formula I that are cGAS antagonists, methods of preparation of the compounds, pharmaceutical compositions comprising the compounds, and their use in medical therapy.
-
公开(公告)号:US20170320829A1
公开(公告)日:2017-11-09
申请号:US15488205
申请日:2017-04-14
IPC分类号: C07D215/38 , C07D277/40 , C07C229/60 , C07C229/56 , C07C215/68 , A61K31/47 , A61K31/41 , A61K31/4418 , A61K31/44 , A61K31/435 , A61K31/426 , A61K31/423 , C07D277/56 , A61K31/4706
CPC分类号: C07D215/38 , A61K31/41 , A61K31/423 , A61K31/426 , A61K31/435 , A61K31/44 , A61K31/4418 , A61K31/47 , A61K31/4706 , C07C215/68 , C07C229/56 , C07C229/60 , C07D277/40 , C07D277/56
摘要: Compositions and methods for treating macular degeneration and other forms of retinal disease whose etiology involves the accumulation of A2E and/or lipofuscin, and, more specifically, for preventing the formation and/or accumulation of A2E are disclosed
-
公开(公告)号:US09708309B2
公开(公告)日:2017-07-18
申请号:US14848649
申请日:2015-09-09
申请人: Oryzon Genomics S.A.
发明人: Alberto Ortega Muñoz , Matthew Colin Thor Fyfe , Marc Martinell Pedemonte , Iñigo Tirapu Fernandez De La Cuesta , Maria de los Ángeles Estiarte-Martinez
IPC分类号: C07D239/02 , C07D413/00 , C07D417/00 , A61K31/505 , A61K31/44 , C07D417/12 , A61K31/433 , A61K31/4245 , A61K31/422 , C07D213/73 , C07D237/20 , C07D239/42 , C07D241/20 , C07D253/07 , C07D261/14 , C07D263/48 , C07D271/07 , C07D271/113 , C07D277/40 , C07D285/12 , C07D401/12 , C07D413/12 , C07D285/135 , C07D285/08
CPC分类号: C07D417/12 , A61K31/422 , A61K31/4245 , A61K31/433 , C07D213/73 , C07D237/20 , C07D239/42 , C07D241/20 , C07D253/07 , C07D261/14 , C07D263/48 , C07D271/07 , C07D271/113 , C07D277/40 , C07D285/08 , C07D285/12 , C07D285/135 , C07D401/12 , C07D413/12
摘要: The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula (I) as described and defined herein, and their use in therapy, including, e.g., in the treatment or prevention of cancer, a neurological disease or condition, or a viral infection. Thus, in one specific aspect the invention relates to formulas (II), (III), (IV), (V), (VI), (VII), (VIII), (IX).
-
公开(公告)号:US09656953B2
公开(公告)日:2017-05-23
申请号:US14171273
申请日:2014-02-03
IPC分类号: C07C279/06 , C07C335/32 , C07C323/45 , C07D233/30 , C07D233/84 , C07D235/08 , C07D249/14 , C07D249/12 , C07D277/42 , C07D277/40 , C07D317/56 , C07D215/12 , C07D213/53 , C07D235/28 , C07D317/58
CPC分类号: C07C323/45 , C07C279/06 , C07C335/32 , C07D213/53 , C07D215/12 , C07D233/30 , C07D233/84 , C07D235/28 , C07D249/12 , C07D249/14 , C07D277/40 , C07D277/42 , C07D317/56 , C07D317/58
摘要: The disclosed modulators of Rb:Raf-1 interactions are potent, selective disruptors of Rb:Raf-1 binding, with IC50 values ranging from 80 nM to 500 nM. Further, these compounds are surprisingly effective in inhibiting a wide variety of cancer cells, including osteosarcoma, epithelial lung carcinoma, non-small cell lung carcinoma, three different pancreatic cancer cell lines, two different glioblastoma cell lines, metastatic breast cancer, melanoma, and prostate cancer. Moreover, the disclosed compounds effectively disrupt angiogenesis and significantly inhibited tumors in nude mice derived from human epithelial lung carcinoma tumors. Accordingly, the disclosed compounds, pharmaceutical compositions comprising the compounds, methods of inhibiting cell proliferation, methods of treating subjects with cancer, and methods of preparing the disclosed compounds are provided.
-
公开(公告)号:US09617256B2
公开(公告)日:2017-04-11
申请号:US14223971
申请日:2014-03-24
申请人: Achaogen, Inc.
发明人: Heinz E. Moser , Qing Lu , Phillip A. Patten , Dan Wang , Ramesh Kasar , Stephen Kaldor , Brian D. Patterson
IPC分类号: C07D471/04 , C07C259/06 , C07D205/04 , C07D207/08 , C07D207/09 , C07D207/10 , C07D207/12 , C07D207/16 , C07D207/32 , C07D207/337 , C07D207/46 , C07D207/48 , C07D209/46 , C07D211/08 , C07D211/26 , C07D211/34 , C07D211/38 , C07D211/46 , C07D211/94 , C07D213/36 , C07D213/38 , C07D213/56 , C07D213/61 , C07D217/22 , C07D217/24 , C07D231/12 , C07D231/14 , C07D231/56 , C07D233/26 , C07D233/36 , C07D233/64 , C07D239/26 , C07D239/42 , C07D239/88 , C07D239/90 , C07D241/12 , C07D241/52 , C07D249/08 , C07D261/08 , C07D261/20 , C07D263/32 , C07D263/34 , C07D263/58 , C07D267/10 , C07D271/107 , C07D275/02 , C07D277/30 , C07D277/40 , C07D277/46 , C07D277/82 , C07D285/12 , C07D295/092 , C07D295/096 , C07D295/135 , C07D295/155 , C07D295/26 , C07D307/14 , C07D309/04 , C07D309/12 , C07D333/06 , C07D333/24 , C07D333/34 , C07D333/36 , C07D335/02 , C07D413/04 , C07D213/74 , C07D239/70
CPC分类号: C07D471/04 , C07C259/06 , C07C311/08 , C07C2601/02 , C07C2601/04 , C07C2601/08 , C07C2601/14 , C07D205/04 , C07D207/06 , C07D207/08 , C07D207/09 , C07D207/10 , C07D207/12 , C07D207/16 , C07D207/32 , C07D207/337 , C07D207/34 , C07D207/46 , C07D207/48 , C07D209/46 , C07D211/08 , C07D211/26 , C07D211/34 , C07D211/38 , C07D211/46 , C07D211/56 , C07D211/94 , C07D213/36 , C07D213/38 , C07D213/56 , C07D213/61 , C07D213/74 , C07D217/22 , C07D217/24 , C07D231/12 , C07D231/14 , C07D231/56 , C07D233/26 , C07D233/36 , C07D233/64 , C07D239/26 , C07D239/42 , C07D239/70 , C07D239/88 , C07D239/90 , C07D241/08 , C07D241/12 , C07D241/52 , C07D249/08 , C07D261/08 , C07D261/20 , C07D263/32 , C07D263/34 , C07D263/58 , C07D267/10 , C07D271/107 , C07D275/02 , C07D277/30 , C07D277/40 , C07D277/46 , C07D277/82 , C07D285/12 , C07D295/092 , C07D295/096 , C07D295/135 , C07D295/15 , C07D295/155 , C07D295/26 , C07D307/14 , C07D309/04 , C07D309/08 , C07D309/12 , C07D333/06 , C07D333/24 , C07D333/34 , C07D333/36 , C07D335/02 , C07D413/04
摘要: Antibacterial compounds of formula (I) are provided: as well as stereoisomers, pharmaceutically acceptable salts, esters, and prodrugs thereof; pharmaceutical compositions comprising such compounds; methods of treating bacterial infections by the administration of such compounds; and processes for the preparation of such compounds.
-
公开(公告)号:US09598385B2
公开(公告)日:2017-03-21
申请号:US14754100
申请日:2015-06-29
申请人: City of Hope
发明人: David Horne , Christopher Lincoln
IPC分类号: C07D277/46 , C07D277/40 , C07C45/68
CPC分类号: C07D277/46 , C07C45/68 , C07D277/40 , C07D417/12
摘要: Provided herein are novel compounds that inhibit ribonucleotide reductase (RR) by binding to RRM2 and interfering with the activity of the RRM1/RRM2 holoenzyme, as well as methods of synthesizing these novel compounds. The compounds may be used to inhibit RR activity and to treat various conditions associated with RRM2 expression, such as for example certain cancer types, mitochondrial diseases, or degenerative diseases.
-
公开(公告)号:US20170066731A1
公开(公告)日:2017-03-09
申请号:US15123218
申请日:2015-03-05
发明人: Nicholas D.P. COSFORD , Jeffrey SMITH , Robert J. ARDECKY , Jiwen ZOU , Margrith MATTMANN , Peter TERIETE , Lester LAMBERT
IPC分类号: C07D277/46 , C07D277/40 , C07D417/04 , C07D277/42 , C07D417/12 , C07D277/26
CPC分类号: C07D277/46 , A61K31/426 , A61K31/427 , A61K31/5377 , C07D277/26 , C07D277/40 , C07D277/42 , C07D417/04 , C07D417/12 , Y02A50/385 , Y02A50/387 , Y02A50/393
摘要: Provided herein are small molecule Fatty Acid Synthase Inhibitors, compositions comprising the compounds, and methods of using the compounds and compositions comprising the compounds.
摘要翻译: 本文提供了小分子脂肪酸合酶抑制剂,包含该化合物的组合物,以及使用该化合物和包含该化合物的组合物的方法。
-
公开(公告)号:US20160068539A1
公开(公告)日:2016-03-10
申请号:US14940817
申请日:2015-11-13
申请人: MEDIVIR AB
IPC分类号: C07D491/048
CPC分类号: C07D277/40 , C07D491/048 , C07D495/04
摘要: Compounds of the formula II: wherein R1 and R2 are independently H, F or CH3; or R1 forms an ethynyl bond and R2 is H or C3-C6 cycloalkyl which is optionally substituted with one or two substituents independently selected from methyl, CF3, OMe or halo; R3 is C1-C3 alkyl or C3-C6 cycloalkyl, either of which is optionally substituted with one or two methyl and/or a fluoro, trifluoromethyl or methoxy, when R3 is C3-C6 cycloalkyl it may alternatively be gem substituted with fluoro; R4 is methyl or fluoro; m is 0, 1 or 2; E is a bond, or thiazolyl, optionally substituted with methyl or fluoro; A1 is CH or N, A2 is CR6R7 or NR6, provided at least one of A1 and A2 comprises N; R6 is H, C1-C4 alkyl, C1-C4 haloalkyl, C1-C3 alkyl-O—C1-C3 alkyl, or when A2 is C, R6 can also be C1-C4 alkoxy or F; R7 is H, C1-C4 alkyl or F or a pharmaceutically acceptable salt, N-oxide or hydrate thereof, have utility in the treatment of disorders characterized by inappropriate expression or activation of cathepsin K, such as osteoporosis, osteoarthritis, rheumatoid arthritis or bone metastases.
摘要翻译: 式II化合物:其中R 1和R 2独立地为H,F或CH 3; 或R1形成乙炔基,R2是H或C3-C6环烷基,其任选地被一个或两个独立地选自甲基,CF 3,OMe或卤素的取代基取代; R 3是C 1 -C 3烷基或C 3 -C 6环烷基,当R 3是C 3 -C 6环烷基时,它们任选被一个或两个甲基和/或氟,三氟甲基或甲氧基取代,也可以被氟取代; R4是甲基或氟; m为0,1或2; E是任选被甲基或氟取代的键或噻唑基; A1是CH或N,A2是CR6R7或NR6,条件是A1和A2中的至少一个包括N; R6是H,C1-C4烷基,C1-C4卤代烷基,C1-C3烷基-O-C1-C3烷基,或当A2是C时,R6也可以是C1-C4烷氧基或F; R7是H,C1-C4烷基或F或其药学上可接受的盐,N-氧化物或其水合物,可用于治疗组织蛋白酶K不适当表达或活化的疾病,例如骨质疏松症,骨关节炎,类风湿性关节炎或骨骼 转移。
-
-
-
-
-
-
-
-
-